Windtree Therapeutics
Pharmaceuticals, 2600 Kelly Rd, Warrington, Pennsylvania, 18976, United States, 11-50 Employees
Phone Number: 21********
Who is WINDTREE THERAPEUTICS
Windtree Therapeutics is a global, clinical-stage, biopharmaceutical and medical device company focused on the development of novel therapeutics intended to address significant unmet medi...
Read More
-
Headquarters: 2600 Kelly Rd, Warrington, Pennsylvania, 18976, United States
-
Date Founded: 1992
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
-
CEO:
Craig Fraser
Email
Phone
Industry: Pharmaceuticals
SIC Code: 2836
|
NAICS Code: 561110 |
Show More
Does something look wrong? Fix it. | View contact records from WINDTREE THERAPEUTICS
Windtree Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Windtree Therapeutics
Answer: Windtree Therapeutics's headquarters are located at 2600 Kelly Rd, Warrington, Pennsylvania, 18976, United States
Answer: Windtree Therapeutics's phone number is 21********
Answer: Windtree Therapeutics's official website is https://windtreetx.com
Answer: Windtree Therapeutics's revenue is $5 Million to $10 Million
Answer: Windtree Therapeutics's SIC: 2836
Answer: Windtree Therapeutics's NAICS: 561110
Answer: Windtree Therapeutics has 11-50 employees
Answer: Windtree Therapeutics is in Pharmaceuticals
Answer: Windtree Therapeutics contact info: Phone number: 21******** Website: https://windtreetx.com
Answer: Windtree Therapeutics is a global, clinical-stage, biopharmaceutical and medical device company focused on the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. Windtree has four clinical and multiple pre-clinical programs spanning respiratory, cardiovascular and oncology disease states. The Companys lead clinical programs include AEROSURF, a novel med-device combination designed to deliver the companys proprietary synthetic, peptide-containing surfactant non-invasively to premature infants with respiratory distress syndrome (RDS); istaroxime, a first-in-class, dual-acting agent being developed to improve cardiac function in patients with acute heart failure while avoiding the unwanted side effects of existing treatments; and rostfuroxin, a novel precision medicine targeting hypertensive patients with certain genetic profiles focused on the large and important resistant hypertension market. In all we do, we are driven by compassion and the aspiration to help patients and their families realize the hope they have for a life less impacted by disease.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
CEO at Windtree Therapeutics
Sign in to CIENCE GO Data to uncover contact details
Free credits every month